ALEC ALECTOR

Alector to Participate in the Stifel Healthcare Conference

Alector to Participate in the Stifel Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced management will participate in a fireside chat at the Stifel Healthcare Conference on Tuesday, November 14, 2023, at 11:30 a.m. ET.

A live webcast of the fireside chat will be available on the “Events & Presentations” page within the Investors section of the Alector website at . A replay will be available on the Alector website for 90 days following the event.

About Alector

Alector is a clinical-stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. Alector has discovered and is developing a broad portfolio of innate immune system programs, designed to functionally repair genetic mutations that cause dysfunction of the brain’s immune system and enable rejuvenated immune cells to counteract emerging brain pathologies. Alector’s immuno-neurology product candidates are supported by biomarkers and seek to treat indications, including Alzheimer’s disease and genetically defined frontotemporal dementia patient populations. Alector is headquartered in South San Francisco, California. For additional information, please visit .

Alector Contacts:

Alector

Katie Hogan

202-549-0557

1AB (media)

Dan Budwick

973-271-6085

Argot Partners (investors)

Laura Perry

212.600.1902



EN
08/11/2023

Underlying

ALECALECTOR

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ALECTOR

 PRESS RELEASE
Free
ALEC ALECTOR

Alector Reports Second Quarter 2025 Financial Results and Provides Bus...

Alector Reports Second Quarter 2025 Financial Results and Provides Business Update On track to report topline data by mid-Q4 2025 from the pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in FTD-GRN, a severe, rare form of dementia with no approved treatments Ongoing Phase 2 PROGRESS-AD trial of AL101 in early Alzheimer’s disease expected to complete in 2026 Continuing to progress Alector Brain Carrier programs, including the company’s anti-amyloid beta antibody, engineered GCase enzyme replacement therapy, and anti-tau siRNA $307.3 million in cash, cash equivalents, and investmen...

August 7, 2025 1 EN
 PRESS RELEASE
Free
ALEC ALECTOR

Alector to Host Second Quarter and Mid-Year 2025 Earnings Conference C...

Alector to Host Second Quarter and Mid-Year 2025 Earnings Conference Call Call Scheduled for Thursday, August 7, 2025, at 4:30 p.m. ET/1:30 p.m. PT SOUTH SAN FRANCISCO, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced it will host a conference call and webcast on Thursday, August 7, 2025, at 4:30 p.m. ET to discuss results for the second quarter ended June 30, 2025, and provide a mid-year business update. The c...

July 31, 2025 1 EN
 PRESS RELEASE
Free
ALEC ALECTOR

Alector Provides Executive Leadership Update

Alector Provides Executive Leadership Update -- Neil Berkley, M.B.A., appointed Interim Chief Financial Officer, succeeding Marc Grasso, M.D., effective June 20, 2025 -- SOUTH SAN FRANCISCO, Calif., June 13, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that its Chief Financial Officer (CFO), Marc Grasso, M.D., will conclude his tenure with the company, effective June 20, 2025, to pursue other opportunities. Neil Berkley, M...

June 13, 2025 1 EN
 PRESS RELEASE
Free
ALEC ALECTOR

Alector to Participate in the Goldman Sachs 46th Annual Global Healthc...

Alector to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference SOUTH SAN FRANCISCO, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that management will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on Tuesday, June 10, 2024, at 8:40 am ET. A live webcast of the fireside chat will be available on the “Events & Presentations” page within the In...

June 3, 2025 1 EN
 PRESS RELEASE
Free
ALEC ALECTOR

Alector Reports First Quarter 2025 Financial Results and Provides Busi...

Alector Reports First Quarter 2025 Financial Results and Provides Business Update Topline data from pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in FTD-GRN on track for Q4 2025 Completed enrollment in PROGRESS-AD Phase 2 clinical trial of AL101 in early Alzheimer’s disease Continuing to pursue Alector Brain Carrier programs, including the company’s anti-amyloid beta antibody and its GCase enzyme replacement therapy Extending runway into the second half of 2027, with $354.6 million in cash, cash equivalents, and investments SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE N...

May 8, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch